Preventive and therapeutic approach to @entity1211 and XXXX --can death from @entity1151 be prevented?

@entity1 @entity583 @entity95 @entity49 @entity1151 @entity1150 @entity887 @entity1031 @entity3859 @entity1211 @entity715 @entity1229
@entity1211 produces chronic sequelae in the legs and occasional immediate mortality due to @entity1151 . Because it occurs in certain high risk situations (for example, after surgery) its prevention is a practical proposition. This has been attempted using many different approaches. Administration of low dose heparin with or without @entity3859 to enhance venous return has been one of the most widely tested regimens. There is little doubt that this can prevent, in many @entity1 groups, postoperative @entity1150 and @entity1151 , with a low incidence of adverse reactions. Some particularly high risk postoperative @entity1 groups (for example, those undergoing hip surgery) warrant more aggressive measures to prevent @entity715 . Surveys have shown that increasing use is being made of this approach, and it is hoped that all surgeons will adopt a policy that will reduce postoperative @entity49 and @entity1151 . A reduction in the incidence of @entity1211 in large acute @entity583 is achieved by low dose heparin, although early mobilization is important. In addition, many of the @entity1 at risk merit full dose anticoagulation to prevent intracardiac @entity1031 . Established @entity49 is treated effectively by intravenous heparin, followed by @entity1229 to keep the prothrombin time at 1.2 to 1.5 times control, as assessed using @entity95 thromboplastin; most @entity1 need three months of treatment. Anticoagulation is warranted for @entity1151 , with fibrinolytic therapy reserved for @entity1 with massive @entity887 and hemodynamic compromise. Embolectomy is a heroic measure, which may occasionally be lifesaving.
